Ensuring Leadership Continuity—The Coleman Health Services Case Study is starting in

ADHD Drugs Associated With An Increased Risk Of Major Depression In Children

Children diagnosed with attention-deficit/hyperactivity disorder (ADHD) and taking the stimulant methylphenidate as treatment were at increased risk of developing major depressive disorder (MDD). After starting methylphenidate, the incidence of MDD in children with ADHD was 18 times higher than children without ADHD. Before starting methylphenidate, their incidence of MDD was 12 times higher than for children without ADHD. After methylphenidate was discontinued, their incidence of MDD declined to the starting level within 60 days.

These findings were reported in “Association between Attention Deficit Hyperactivity Disorder Medication and Depression: A 10-year Follow-up Self-controlled Case Study” by . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.